Announced Thu, 23 Jul · 16:40 IST
No deviation in Rights Issue fund use for Q1FY27
Compliance View source PDF
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.9%1-day move
₹522.60
prior close
₹521.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-1.3-1.3-1.7-3.9—————————
Up moveDown movePending
AI summary
Solara Active Pharma Sciences confirms no deviation or variation in use of Rs 442.73 crore raised via Rights Issue for quarter ended June 30, 2026. Rs 333.61 crore used for repaying borrowings against Rs 334.71 crore allocated. Rs 105.02 crore used for general corporate purposes from Rs 112.24 crore allocated. Total Rs 438.63 crore utilized; Rs 1.10 crore remains in escrow and monitoring accounts. Audit Committee and CRISIL Ratings reviewed and approved.
Likely market impact
Confirms disciplined use of Rights Issue proceeds with no diversion. Borrowings reduced as planned. Neutral to mildly positive for shareholders.